ALLO
Allogene Therapeutics, Inc. · Healthcare
Insiders sold $271K of Allogene Therapeutics, Inc. in the last 12 months and bought none
ALLO over the last year
ALLO after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
68 insider filings since 2018, newest first
Geoffrey M. Parker · Chief Financial Officer
Earl Martin Douglas · SVP and General Counsel
David D Chang · President and CEO
Zachary Roberts · EVP of R, D
Deborah M. Messemer · Director
Franz B Humer · Director
Arie Belldegrun · Director
Deborah M. Messemer · Director
Stephen Mayo · Director
Veer Bhavnagri · General Counsel
Owen N. Witte · Director
Owen N. Witte · Director
Rafael Amado · EVP of R, D, CMO
Rafael Amado · EVP of R, D, CMO
Veer Bhavnagri · General Counsel
David D Chang · President and CEO
Eric Thomas Schmidt · CFO
Alison Moore · Chief Technical Officer
Joshua A Kazam · Director
Arie Belldegrun · Director
Rafael Amado · EVP of R, D, CMO
Veer Bhavnagri · General Counsel
Owen N. Witte · Director
Owen N. Witte · Director
Veer Bhavnagri · General Counsel
Veer Bhavnagri · General Counsel
Veer Bhavnagri · General Counsel
Owen N. Witte · Director
Veer Bhavnagri · General Counsel
Veer Bhavnagri · General Counsel
Veer Bhavnagri · General Counsel
Rafael Amado · EVP of R, D, CMO
David D Chang · President and CEO
Alison Moore · Chief Technical Officer
Veer Bhavnagri · General Counsel
Eric Thomas Schmidt · CFO
Eric Thomas Schmidt · CFO
Eric Thomas Schmidt · CFO
Eric Thomas Schmidt · CFO
Alison Moore · Chief Technical Officer
Alison Moore · Chief Technical Officer
Rafael Amado · EVP of R, D, CMO
Alison Moore · Chief Technical Officer
Veer Bhavnagri · General Counsel
Rafael Amado · EVP of R, D, CMO
Veer Bhavnagri · General Counsel
Eric Thomas Schmidt · CFO
Veer Bhavnagri · General Counsel
Tpg Group Holdings (Sbs) Advisors, Inc. · 10% owner
Veer Bhavnagri · General Counsel
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.